Bivatuzumab (previously BIWA 4) is a humanized monoclonal antibody against CD44 v6. A31688,A31689
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Bivatuzumab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Bivatuzumab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Bivatuzumab. |
| Estrone | Estrone may increase the thrombogenic activities of Bivatuzumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Bivatuzumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Bivatuzumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Bivatuzumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Bivatuzumab. |
| Estriol | Estriol may increase the thrombogenic activities of Bivatuzumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Bivatuzumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Bivatuzumab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Bivatuzumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Bivatuzumab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Bivatuzumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Bivatuzumab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Bivatuzumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Bivatuzumab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Bivatuzumab. |
| Equol | Equol may increase the thrombogenic activities of Bivatuzumab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Bivatuzumab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Bivatuzumab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Bivatuzumab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Bivatuzumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Bivatuzumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Bivatuzumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Bivatuzumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Bivatuzumab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Bivatuzumab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Bivatuzumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Bivatuzumab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Bivatuzumab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Bivatuzumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Bivatuzumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Bivatuzumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Bivatuzumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bivatuzumab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bivatuzumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Bivatuzumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Bivatuzumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Bivatuzumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Bivatuzumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Bivatuzumab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bivatuzumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bivatuzumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Bivatuzumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bivatuzumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bivatuzumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Bivatuzumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bivatuzumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Bivatuzumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Bivatuzumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Bivatuzumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bivatuzumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Bivatuzumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Bivatuzumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Bivatuzumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Bivatuzumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Bivatuzumab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Bivatuzumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Bivatuzumab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Bivatuzumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Bivatuzumab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Bivatuzumab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Bivatuzumab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Bivatuzumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Bivatuzumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Bivatuzumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Bivatuzumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Bivatuzumab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Bivatuzumab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Bivatuzumab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Bivatuzumab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Bivatuzumab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Bivatuzumab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Bivatuzumab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Bivatuzumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Bivatuzumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Bivatuzumab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Bivatuzumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Bivatuzumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Bivatuzumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Bivatuzumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Bivatuzumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Bivatuzumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Bivatuzumab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Bivatuzumab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Bivatuzumab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Bivatuzumab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Bivatuzumab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Bivatuzumab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Bivatuzumab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Bivatuzumab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Bivatuzumab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Bivatuzumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Bivatuzumab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Bivatuzumab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Bivatuzumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Bivatuzumab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Bivatuzumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Bivatuzumab. |